25 Mar 2020
EUR 750 million
|Date of agreement:||5 Jul 2017|
|Customer:||Chr. Hansen Holding A/S|
|Amount in EUR:||EUR 50 million|
|NACE sector / loan type:||Research and development|
|Business area:||Industries and services|
The loan has been provided to finance Chr. Hansen Holding A/S’s research and development programme in 2017–2018. The programme has a total budget of EUR 150 million and will focus on process optimisation and development of new innovative products.
Chr. Hansen’s R&D activities are driven by customer demand, which includes demand for cleaner food and beverage products. For instance, the field of bio-protection focuses on keeping food products fresh for longer while reducing chemical additives. The R&D projects are also aimed at new fields, such as plant and animal health.
Founded in 1874, Chr. Hansen Holding A/S is a global supplier of bioscience-based ingredients to the food, health and animal feed industries. The company produces cultures and dairy enzymes, probiotics and natural colours.
This loan will benefit competitiveness by adding value to in-house capacity and bioscience innovations. Chr. Hansen is a pioneer in probiotics, and its portfolio features some of the most-documented bacterial strains. The company’s R&D programme is geared towards customer needs and employs leading enzyme technology to deliver unique microbial solutions for a wide range of industries. As maintaining a technological edge is the key to growth in the bioscience industry, excellent performance in innovation is crucial.
The programme includes more than 100 R&D projects, half of which are within the fresh dairy and cheese sector.
No significant environmental issues are expected to arise from the R&D programme.